CervoMed Inc. (CRVO)
NASDAQ: CRVO · Real-Time Price · USD
8.83
+0.58 (7.03%)
At close: Aug 1, 2025, 4:00 PM
8.64
-0.19 (-2.15%)
After-hours: Aug 1, 2025, 7:56 PM EDT
Company Description
CervoMed Inc., a a clinical-stage biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders.
The company is developing neflamapimod, an orally administered small molecule brain penetrant that inhibits p38 mitogen-activated protein kinase alpha.
Neflamapimod has the potential to treat synaptic dysfunction, the reversible aspect of the underlying neurodegenerative processes that cause disease in DLB and certain other major neurological disorders.
It is being evaluated in a Phase 2b study in patients with DLB. The company develops EIP200 for central nervous system which is in preclinical trials.
CervoMed Inc. was founded in 2010 and is headquartered in Boston, Massachusetts.
CervoMed Inc.
| Country | United States |
| Founded | 2001 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 15 |
| CEO | John Alam |
Contact Details
Address: 20 Park Plaza, Suite 424 Boston, Massachusetts 02116 United States | |
| Phone | 617 744 4400 |
| Website | cervomed.com |
Stock Details
| Ticker Symbol | CRVO |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001053691 |
| CUSIP Number | 15713L109 |
| ISIN Number | US15713L1098 |
| Employer ID | 30-0645032 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. John J. Alam M.D. | Co-Founder, Chief Executive Officer, President and Director |
| Dr. Sylvie L. Gregoire Pharm.D. | Co-Founder and Director |
| William Robert Elder J.D. | Chief Financial Officer, General Counsel and Corporate Secretary |
| Dr. Marinus Verwijs Ph.D. | Executive Vice President of Technical Operations |
| Kelly Blackburn M.H.A. | Executive Vice President of Clinical Development |
| Dr. Mark A. De Rosch Ph.D. | Executive Vice President of Regulatory, Government Affairs and Program Management |
| Dr. Claudia Ordonez M.D. | Senior Vice President of Medical Science |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jul 28, 2025 | 8-K | Current Report |
| Jun 25, 2025 | 8-K | Current Report |
| May 19, 2025 | 8-K | Current Report |
| May 12, 2025 | 424B5 | Filing |
| May 12, 2025 | 8-K | Current Report |
| May 12, 2025 | 10-Q | Quarterly Report |
| May 7, 2025 | SCHEDULE 13G | Filing |
| Apr 30, 2025 | ARS | Filing |
| Apr 29, 2025 | DEF 14A | Other definitive proxy statements |
| Apr 18, 2025 | 8-K | Current Report |